Management and outcome of EGFR mutant lung cancer with SARS-CoV-2 infection.

Kolluri, Spoorthy; Panda, Soumya Surath; Panda, Adyakinkar; Singh, Santosh Kumar

Kolluri, Spoorthy; Panda, Soumya Surath; Panda, Adyakinkar; Singh, Santosh Kumar.

Afiliación

Kolluri S; Department of Medical Oncology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India.
Panda SS; Department of Medical Oncology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India.
Panda A; Department of Radiology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India.
Singh SK; Department of Medicine, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India.

J Cancer Res Ther ; 19(5): 1454-1456, 2023.

Article en En | MEDLINE | ID: mdl-37787329

Asunto(s)

COVID-19; Neoplasias Pulmonares; Masculino; Humanos; Neoplasias Pulmonares/complicaciones; Neoplasias Pulmonares/diagnóstico; Neoplasias Pulmonares/tratamiento farmacológico; SARS-CoV-2; Gefitinib; Receptores ErbB/genética

Palabras clave

COVID-19; EGFR mutant lung cancer; tyrosine kinase inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Neoplasias Pulmonares Tipo de estudio: Guideline Límite: Humans / Male Idioma: En Revista: J Cancer Res Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: India

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google